Faheem Hasnain
CIK 1352620 · President & CEO · last filed 2026-08-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RCPT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3115 MERRYFIELD ROW, SUITE 120
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GOSS | President & CEO | 78,073 | $8.43 | $658.2K | $3.22M | 22 | 2026-08-26 |
| KURA | Director | 23,983 | $9.36 | $224.5K | -$291.2K | 13 | 2026-06-04 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Director | 10,791 | $58.70 | $633.4K | $300.0K | 8 | 2024-01-23 |
| Nuvation Bio Inc. (NUVB.WS) Delisted | Director | 55,000 | $0.01 | $280 | $0 | 1 | 2021-02-26 |
| Forte Biosciences, Inc. (TOCA) Delisted | Director | 16,114 | — | — | $1.20M | 5 | 2019-10-04 |
| Receptos, Inc. (RCPT) Delisted | President & CEO | 0 | — | — | -$21.89M | 5 | 2015-08-27 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Director | — | $0.54 | — | $0 | 3 | 2014-11-12 |
| Pernix Sleep, Inc. (SOMX) Delisted | Director | 24,519 | — | — | $0 | 7 | 2013-01-03 |
| FACT | President & CEO | 102,667 | $10.75 | $1.10M | $0 | 4 | 2010-04-21 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | President & CEO | 125,000 | — | — | $0 | 1 | 2008-10-03 |
| BIIB | EVP, Oncology/Rheumatology SBU | 25,454 | $233.48 | $5.94M | -$3.43M | 12 | 2008-07-10 |
| TERCICA INC (TRCA) Delisted | Director | — | $7.87 | — | $0 | 1 | 2008-02-28 |
Recent Filings · Page 8 of 10
95 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-07-03 | Pernix Sleep, Inc. (SOMX) Delisted | Grant (A) | +45,789 | $0 | EDGAR |
| 2012-06-04 | Pernix Sleep, Inc. (SOMX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-04-04 | Pernix Sleep, Inc. (SOMX) Delisted | Grant (A) | +59,423 | $0 | EDGAR |
| 2011-06-03 | Pernix Sleep, Inc. (SOMX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-09-20 | Pernix Sleep, Inc. (SOMX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-04-23 | — | Disp (D) | −102,667 | -$2.77M | |
| 2010-04-21 | FACT | U | −18,463 | -$498.5K | EDGAR |
| 2009-10-05 | FACT | Tax (F) | −8,937 | -$155.2K | EDGAR |
| 2009-08-10 | FACT | Grant (A) | +27,667 | $0 | EDGAR |
| 2009-01-27 | FACT | Grant (A) | +100,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.